Performance of the Corporate Broking & Advisory division was in line with H2 last year, but below the comparative period, whereas average deal fees remained in line with the previous year. Deals transaction volumes and institutional income were both nearly 25% lower than the previous year.
The company does not expect a material change in the overall value of payments for research and sales offering this year. Investments in 2018 significantly support the strategic desire to deliver market share gains in core products and progress further in adjacent product areas.
The company expects a significant increase in revenue with regard to the UK macroeconomic and political landscape.